{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:00:52Z","timestamp":1753891252810,"version":"3.41.2"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Early stable deep molecular response (DMR) to nilotinib is associated with goal of treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP). It is important to early distinguish between patients who can achieve a DMR and those who are fit for TFR.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a multicenter study to explore the early cumulative MR<jats:sup>4.5<\/jats:sup> rate at 18\u2009months with nilotinib in patients with newly diagnosed CML-CP (ND-CML-CP) in China. Of the 29 institutes, 106 patients with ND-CML-CP received nilotinib (300\u2009mg BID).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results and discussion<\/jats:title><jats:p>The cumulative MR<jats:sup>4.5<\/jats:sup> rate of nilotinib treatment at 18\u2009months was 69.8% (74\/106). The cumulative MMR and MR<jats:sup>4.0<\/jats:sup> rates for nilotinib at 18\u2009months were 94.3% (100\/106) and 84.9% (90\/106), respectively. Patients with an ultra-early molecular response (u-EMR) at 6\u2009weeks were not significantly different in obtaining DMR or MMR by 24\u2009months compared with those without u-EMR (<jats:italic>p<\/jats:italic>\u2009=\u20090.7584 and <jats:italic>p<\/jats:italic>\u2009=\u20090.9543, respectively). Our study demonstrated that nilotinib treatment in patients with ND-CML-CP contributed to obtain high early MR<jats:sup>4.5<\/jats:sup>.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1267512","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T14:20:37Z","timestamp":1700144437000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China"],"prefix":"10.3389","volume":"10","author":[{"given":"Bingbing","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuangqing","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yirong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zelin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wangxiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1016\/j.clml.2015.02.035","article-title":"Mutations in the BCR-ABL1 kinase domain and elsewhere in chronic myeloid leukemia","volume":"15","author":"Soverini","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/cncr.11520","article-title":"Chronic myelogenous leukemia: a review and update of therapeutic strategies","volume":"98","author":"Garcia-Manero","year":"2003","journal-title":"Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1586\/14737140.4.1.85","article-title":"Clinical and epidemiologic burden of chronic myelogenous leukemia","volume":"4","author":"Redaelli","year":"2004","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European leukemia net recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"volume-title":"NCCN clinical practice guidelines in oncology","year":"2023","key":"ref6"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4941","DOI":"10.1158\/1078-0432.CCR-04-2601","article-title":"AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia","volume":"11","author":"Golemovic","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4855","DOI":"10.1182\/bloodadvances.2020003235","article-title":"Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel","volume":"5","author":"Pavlovsky","year":"2021","journal-title":"Blood Adv"},{"volume-title":"NCCN clinical practice guidelines in oncology","year":"2022","key":"ref16"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities","volume":"121","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2013-06-511592","article-title":"Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)","volume":"123","author":"Jabbour","year":"2014","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s12185-019-02613-1","article-title":"Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the new TARGET system","volume":"109","author":"Kizaki","year":"2019","journal-title":"Int J Hematol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.1182\/blood-2012-10-462291","article-title":"Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML","volume":"121","author":"Branford","year":"2013","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1007\/s00432-017-2359-9","article-title":"Nilotinib first-line therapy in patients with Philadelphia chromosome-negative\/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis","volume":"143","author":"Hochhaus","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1002\/cam4.3034","article-title":"Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR (4.5)): the phase 2, multicenter N-road study","volume":"9","author":"Nishiwaki","year":"2020","journal-title":"Cancer Med"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12032-018-1093-8","article-title":"Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase","volume":"35","author":"Tokuhira","year":"2018","journal-title":"Med Oncol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am J Hematol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/cncr.32623","article-title":"Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia","volume":"126","author":"Masarova","year":"2020","journal-title":"Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/cncr.32627","article-title":"Long-term results of frontline dasatinib in chronic myeloid leukemia","volume":"126","author":"Maiti","year":"2020","journal-title":"Cancer"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-Na\u00efve chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1267512\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T14:20:49Z","timestamp":1700144449000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1267512\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":31,"alternative-id":["10.3389\/fmed.2023.1267512"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1267512","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2023,11,16]]},"article-number":"1267512"}}